Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-04-02 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于召开2024年度网上业绩说明会的公告
Report Publication Announcement Classification · 95% confidence The document is an announcement about the scheduling of an online earnings explanation meeting (业绩说明会) related to the company's 2024 Annual Report, which was previously disclosed (announcement number 2025-021). The document invites investors to participate in the meeting and submit questions. It does not contain the actual annual report or financial data but rather serves as a notice for an upcoming event to discuss the annual report. The document length is short (801 characters) and it references the annual report as already published elsewhere. Therefore, this is a Report Publication Announcement or related event announcement rather than the Annual Report itself.
2025-04-02 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2024年度内部控制评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report Verification Opinion" issued by CITIC Securities as the sponsor for Jinling Pharmaceutical Co., Ltd. It discusses the internal control evaluation work, standards for identifying internal control deficiencies, and the verification opinion on the 2024 internal control evaluation report. The content focuses on internal control assessment, compliance with regulations, and the sponsor's verification procedures. It is not a full annual report, audit report, or financial statement but rather a verification opinion on the internal control evaluation report. This type of document aligns with an Audit Report / Information (AR) category, as it involves audit-related verification and internal control evaluation results without being a full annual report or standalone financial statements. The document length (4519 characters) and detailed content support this classification rather than a brief announcement or regulatory filing. FY 2024
2025-03-30 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2024年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion report by CITIC Securities regarding the 2024 annual fundraising funds deposit and usage situation of Jinling Pharmaceutical Co., Ltd. It includes detailed financial figures about the amount raised, usage, balance, and management of the funds, as well as compliance with regulatory requirements. The document references regulatory guidelines and includes an auditor's verification report. It is not a general annual report or earnings release but a specialized report focused on the use and management of fundraising proceeds. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is substantial (over 10,000 characters) and contains substantive financial data and analysis related to fundraising usage, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2025-03-30 Chinese
2024年年度审计报告
Regulatory Filings
2025-03-28 Chinese
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告全文" which translates to "2024 Annual Report Full Text" for Jinling Pharmaceutical Company Limited. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive disclosures typical of an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-03-28 Chinese
2025年第二次独立董事专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the company's related party transactions for the year 2024. It references compliance with company law, securities law, and stock exchange regulations, and it is dated March 24, 2025. The content is focused on the review and approval of specific agenda items for a board meeting, rather than presenting financial data or results. The document is short (554 characters) and does not contain financial statements or detailed financial analysis. It is essentially a board/management related announcement about governance and oversight activities, specifically the independent directors' review and opinion. Therefore, it fits best under Board/Management Information (MANG).
2025-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.